Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GCK | P35557 | 4/20 | 0.35 |
| ▸ | LPO | P22079 | 1/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | ATG7 | O95352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14301814 | 0.76 | CBLB (0.43) | KMT2AKDM4EMEN1HPGDHSD17B10 | |
| SCHEMBL1330612 | 0.75 | LMNA (0.43) | KMT2AKDM4EMEN1HPGDHSD17B10 | |
| SCHEMBL1719291 | 0.75 | GAA (0.40) | KMT2AKDM4EMEN1HPGDHSD17B10 | |
| SCHEMBL9048818 | 0.72 | MYC (0.42) | KMT2AKDM4EMEN1HPGDHSD17B10 | |
| SCHEMBL5654722 | 0.71 | GCK (0.46) | KMT2AMEN1HPGDHSD17B10NPSR1 | |
| SCHEMBL8938457 | 0.69 | LPO (0.48) | KMT2AKDM4EMEN1HPGDHSD17B10 | |
| SCHEMBL11734656 | 0.68 | GCK (0.52) | KMT2AMEN1HSD17B10NPSR1ALDH1A1 | |
| SCHEMBL762945 | 0.68 | — | — | |
| SCHEMBL3531433 | 0.67 | GCK (0.52) | KMT2AKDM4EMEN1HPGDHSD17B10 | |
| SCHEMBL15003938 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2452683-A2 | Methods for treating atherosclerosis | Amgen Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| EP-2037928-B1 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC (US) | 2012-01-11 | — | — | EP | disclosed |
| WO-2008002591-A2 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC (US) | 2008-01-03 | — | — | WO | disclosed |